Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26102395 | 1.00 | TSHR (0.39) | TSHRCYP4F2CYP4A11KMT2ALMNA | |
| SCHEMBL11106500 | 0.85 | CYP2C19 (0.37) | TSHRCYP4F2CYP4A11KMT2ALMNA | |
| SCHEMBL29328600 | 0.81 | CYP4F2 (0.38) | TSHRCYP4F2CYP4A11NPSR1 | |
| SCHEMBL10685038 | 0.80 | CYP2C19 (0.37) | TSHRCYP4F2CYP4A11EPHX2ALDH1A1 | |
| SCHEMBL29328591 | 0.80 | CYP4F2 (0.40) | TSHRCYP4F2CYP4A11 | |
| SCHEMBL29168788 | 0.79 | SIRT2 (0.40) | TSHRCYP4F2CYP4A11KMT2AMEN1 | |
| SCHEMBL31369191 | 0.79 | CYP4F2 (0.36) | TSHRCYP4F2CYP4A11NPSR1ALDH1A1 | |
| SCHEMBL26135862 | 0.79 | TSHR (0.41) | TSHRCYP4F2CYP4A11KMT2ALMNA | |
| SCHEMBL28553004 | 0.78 | SIRT2 (0.43) | CYP4F2CYP4A11 | |
| SCHEMBL8468255 | 0.78 | CYP2C19 (0.34) | TSHRCYP4F2CYP4A11NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163030-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4423078-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-118139858-A | Pyrazin-3 (2H) -one derivatives | 吉利德科学公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20230183216-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230183216-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230183216-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| WO-2023076983-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076983-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163030-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | PIR, CYP3A43, CYP1A2 | TSHR 2222/4885CYP4F2 13/4885CYP4A11 43/4885 |
| US-20230183216-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | PIR, CYP3A43, CYP1A2 | TSHR 2222/4885CYP4F2 13/4885CYP4A11 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.